NCT05588817

Brief Summary

Rheumatoid arthritis (RA) is known as a long-lasting inflammatory autoimmune disease affecting the diarthrodial joints, which is diagnosed by inflammation and hyperplasia in synovium, generation of RF and anti-citrullinated protein antibody (ACPA), deformity of cartilage and bone, systemic injuries involving cardiovascular, pulmonary, psychological, and skeletal disorders (McInnes and Schett., 2011).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 18, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 20, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

December 30, 2022

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

October 20, 2022

Status Verified

October 1, 2022

Enrollment Period

11 months

First QC Date

October 18, 2022

Last Update Submit

October 19, 2022

Conditions

Rheumatoid Arthritis (RA)

Outcome Measures

Primary Outcomes (1)

  • rs1059703 PCR polymorphism in rhomatoid arthritis patients

    PCR polymorphism

    1 year

Study Arms (2)

Group 1

ACTIVE COMPARATOR

Normal control

Genetic: PCR polymorphism

Group 2

ACTIVE COMPARATOR

Diagnosed Rhomatoid arthritis patients

Genetic: PCR polymorphism

Interventions

PCR polymorphismGENETIC

PCR polymorphism in Rhomatoid arthritis patients in Egypt

Group 1Group 2

Eligibility Criteria

Age17 Years - 85 Years
Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • approval to sign an informed written consent, patient diagnosed rheumatoid arthritis, patient age range 17-85 year and both sexes are included.

You may not qualify if:

  • Refusal to sign an informed written consent and patient with other autoimmune disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag university hospital

Sohag, Egypt

RECRUITING

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Central Study Contacts

Alaa A Abdel salam, Assistant lecturer

CONTACT

01099058889alaa.eisa@med.sohag.edu.eg

Esam M Abulfadl, Professor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant lecturer

Study Record Dates

First Submitted

October 18, 2022

First Posted

October 20, 2022

Study Start

December 30, 2022

Primary Completion

December 1, 2023

Study Completion

December 1, 2023

Last Updated

October 20, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will share

Locations

EG(1)